These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 25693004)

  • 1. A randomized, double blind, placebo-controlled, multicenter phase II trial of Allisartan Isoproxil in essential hypertensive population at low-medium risk.
    Li Y; Li XH; Huang ZJ; Yang GP; Zhang GG; Zhao SP; Guo Y; Lu SJ; Ma JL; Meng FB; Chen P; Yuan H
    PLoS One; 2015; 10(2):e0117560. PubMed ID: 25693004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Allisartan Isoproxil in the Treatment of Mild-to-Moderate Essential Hypertension.
    Wang H; Xi Y; Chen Y; Wang L; Yang F; Lu X; Sun N
    Am J Hypertens; 2023 Sep; 36(10):561-567. PubMed ID: 37343187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allisartan Isoproxil Improves Endothelial Function and Vascular Damage in Patients with Essential Hypertension: A Single-Center, Open-Label, Randomized Controlled Trial.
    Zhang G; Fan Y; Qiu Y; Zhou Z; Zhang J; Wang Z; Liu Y; Liu X; Tao J
    Adv Ther; 2020 Aug; 37(8):3551-3561. PubMed ID: 32583313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of allisartan isoproxil on blood pressure and target organ injury in patients with mild to moderate essential hypertension.
    Zhang JQ; Yang GH; Zhou X; Liu JX; Shi R; Dong Y; Chen SB; Li YM
    Medicine (Baltimore); 2019 Mar; 98(12):e14907. PubMed ID: 30896643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of allisartan-isoproxil-based combination antihypertensive regimen in hypertensive patients with microalbuminuria or hyperuricemia.
    Sun N; Wang H
    J Clin Hypertens (Greenwich); 2024 Mar; 26(3):241-250. PubMed ID: 38319613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients with Mild to Moderate Essential Hypertension.
    Lee JH; Yang DH; Hwang JY; Hur SH; Cha TJ; Kim KS; Kim MH; Chun KJ; Cha GS; Hong GR; Lee SG; Kim DS; Kim DI; Chae SC
    Clin Ther; 2016 Jun; 38(6):1485-1497. PubMed ID: 27161546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of 30-mg fimasartan for the treatment of patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, phase III clinical study.
    Youn JC; Ihm SH; Bae JH; Park SM; Jeon DW; Jung BC; Park TH; Lee NH; Song JM; Yoon YW; Shin ES; Sung KC; Jung IH; Pyun WB; Joo SJ; Park WJ; Shin JH; Kang SM
    Clin Ther; 2014 Oct; 36(10):1412-21. PubMed ID: 25092393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety evaluation of Allisartan Isoproxil in patients with hypertension: a meta-analysis.
    Zhao F; Liu Y; Chen L
    Front Cardiovasc Med; 2024; 11():1355014. PubMed ID: 38903964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
    Lee H; Yang HM; Lee HY; Kim JJ; Choi DJ; Seung KB; Jeon ES; Ha JW; Rim SJ; Park JB; Shin JH; Oh BH
    Clin Ther; 2012 Jun; 34(6):1273-89. PubMed ID: 22608107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive efficacy of olmesartan medoxomil and ramipril in elderly patients with mild to moderate hypertension grouped according to renal function status : a retrospective analysis.
    Malacco E; Omboni S; Mallion JM; Volpe M;
    High Blood Press Cardiovasc Prev; 2012 Dec; 19(4):213-22. PubMed ID: 23430666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of sacubitril/allisartan for the treatment of primary hypertension: a phase 2 randomized, double-blind study.
    Zhang J; Zhang W; Yan J; Ge Q; Lu XH; Chen SX; Xu WJ; Li Y; Li JF; He SY; Wang JG
    Hypertens Res; 2023 Aug; 46(8):2024-2032. PubMed ID: 37258625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study.
    Volpe M; Brommer P; Haag U; Miele C
    Clin Drug Investig; 2009; 29(1):11-25. PubMed ID: 19067471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
    Lee SE; Kim YJ; Lee HY; Yang HM; Park CG; Kim JJ; Kim SK; Rhee MY; Oh BH;
    Clin Ther; 2012 Mar; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
    Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambulatoria Presión Arterial APROVEL).
    Coca A; Calvo C; García-Puig J; Gil-Extremera B; Aguilera MT; de la Sierra A; Martín-Hidalgo A; Marín R;
    Clin Ther; 2002 Jan; 24(1):126-38. PubMed ID: 11833827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allisartan isoproxil reduces mortality of stroke-prone rats and protects against cerebrovascular, cardiac, and aortic damage.
    Ling QS; Zhang SL; Tian JS; Cheng MH; Liu AJ; Fu FH; Liu JG; Miao CY
    Acta Pharmacol Sin; 2021 Jun; 42(6):871-884. PubMed ID: 34002042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly mild to moderate essential hypertensive patients with or without metabolic syndrome: a pooled post hoc analysis of two comparative trials.
    Omboni S; Malacco E; Mallion JM; Volpe M
    Drugs Aging; 2012 Dec; 29(12):981-92. PubMed ID: 23179896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension.
    Lee H; Kim KS; Chae SC; Jeong MH; Kim DS; Oh BH
    Clin Ther; 2013 Sep; 35(9):1337-49. PubMed ID: 23932463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.
    Barrios V; Boccanelli A; Ewald S; Girerd X; Heagerty A; Krzesinski JM; Lins R; Rodicio J; Stefenelli T; Woittiez A; Böhm M
    Clin Drug Investig; 2007; 27(8):545-58. PubMed ID: 17638395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.